RecruitingEarly Phase 1NCT06612411

B.Subtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Biosynthesis

Purine Starvation Driven by Host-microbiota Maladaptation Contributes to the Pathogenesis of Irritable Bowel Syndrome


Sponsor

Jinling Hospital, China

Enrollment

180 participants

Start Date

Jun 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This is a prospective, single-blind, randomized parallel study to investigate whether B. subtilis could improve clinical symptoms of IBS-D patients. Patients are randomly assigned by envelope method. A senior gastroenterologist is responsible for prescribing medication. Researchers are blind to patients' medication. Participants with IBS are recruited and randomized to receive a 4-week administration of B. subtilis-based probiotics. Clinical symptoms and stool samples are collected before and after the trial.


Eligibility

Min Age: 16 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called B. subtilis and a drug called Dead B. subtilis for people with irritable bowel syndrome with diarrhea and purine metabolism disorder. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 16 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGB. subtilis

2 capsules, 3 times a day, orally taken for one month

DRUGDead B. subtilis

2 capsules, 3 times a day, orally taken for one month


Locations(2)

Jinling Hospital

Nanjing, China

Jinling Hospital

Nanjing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06612411


Related Trials